TY  - CHAP
AU  - Span, Ingrid
AU  - Etzkorn, Manuel
A3  - Barciszewski, Jan
TI  - RNA-Processing DNAzymes
VL  - 14
CY  - Cham
PB  - Springer International Publishing
M1  - FZJ-2024-02998
SN  - 978-3-031-36389-4
T2  - RNA Technologies
SP  - 629 - 643
PY  - 2023
AB  - The great potential of nucleic acids as therapeutics has been recognized for a while but has experienced a tremendous attention with the recent development of RNA vaccines. In contrast to protein-targeting strategies, nucleic acid-based approaches often have the advantage that the required target selectivity is not realized via matching a specific structure, but plainly via the primary sequence of the applied RNA or DNA construct. This sequence is then either directly processed or comprises an additional unit capable of processing a target molecule. The latter is true for a number of DNA sequences, called DNAzymes, that are capable of both binding and processing a target with a high selectivity. While the mRNA technology has the inherent strength of bringing something into the system, RNA-processing DNA catalysts such as RNA-cleaving DNAzymes have the inherent strength of taking something out of the system. Consequently, the DNAzyme technology has the potential to emerge as counterpart to the mRNA technology. However, and in line with the endeavors that were required for the success of the mRNA technology, specific improvements need to be realized to unravel the full potential of RNA-processing DNAzymes. This review provides an overview of recent findings and remaining limitations.
LB  - PUB:(DE-HGF)7
DO  - DOI:10.1007/978-3-031-36390-0_28
UR  - https://juser.fz-juelich.de/record/1025604
ER  -